{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-286961","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.065989+00:00","generated_at":"2026-05-16T18:22:25.302856+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes","bullets":["DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.","All patients reached Week 8; ~25% received second planned DURAVYU dose at Week 32.","Masked safety data shows no safety signals, consistent with prior DURAVYU trials.","Topline 56-week data for LUGANO on track for mid-2026; LUCIA data to follow closely."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-286961","json":"https://secwatch.observer/filing/0001193125-25-286961.json","markdown":"https://secwatch.observer/filing/0001193125-25-286961.md","text":"https://secwatch.observer/filing/0001193125-25-286961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/0001193125-25-286961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:22:25.302856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}